07-04-Erwinaze-Annual-Pricing英文学习资料 .pdfVIP

8.112/2014 EssaxWoodlands Naws-VVilll U.SApprol.al, EUSASstTo PrCM ValueclTransallantic Spec Phema Model -Ant Orptlll1 Focus II EssexWoodlands News With U.S Approval, EUSA Set To Prove Value of Transatlantic Spec Pharma Model - And Orphan Focus Nov222011 Executive Summary U.S approval of orphan drug Erwinase puts specialty pharma firm EUSA on new growth trajectory, showing the value of its strategy to build a transatlantic infrastructure for niche products - and transitioning itfrom a commercially-focused to a development-capable organization. EUSA Pharma Ltd.s investors promised back in April 2011 that the companys acute lymphoblastic leukemia drug Erwinase (asparaginase Erwinia chrysanthemi) had the potential to be a company-maker drug for the group - bywhich they meant an asset that could double or triple the firms revenues and set iton a new growth trajectory. Following Erwinases Nov. 18 FDA approval, Petri Vainio, managing director at private equityfirm and founding investor EssexWoodlands Health Ventures, is sticking to his guns.(EUSA Wins U.S.Approval of Erwinase; Shipping To Start Week Of Nov. 20 - The Pink Sheet DAILY, Nov. 18,2011) This [approval and subsequent launch] will dramatically accelerate EUSAs revenue growth rate and improve the companys profitability, he said, giving itthe resources to build a rapidly-growing, profitable specialty pharma company. Its a goa I that several of the latest-generation of Europes in-1 icensing-focused biopharma firms are striving for, butwhich few have achieved. Repeating the spectacular success of Shire PLC,which grew from its U.K roots to become an international biopharma firm with a market capitalization of over £11 billion ($17 billion), has proven harder than anticipated (Specialty Pharma In Europe: Is Long-Term Independence